PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Expanded Research Lab to Apply Latest Scientific Advances -- Including Stem Cell Research and Gene Editing -- to Accelerate New Treatments for CF
Sept. 16, 2016
|
3 min read
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF
April 16, 2015
|
3 min read
Aug. 11, 2014
|
1 min read